ArticleFrontiers in pharmacology2025
Cornuside mitigates acute lung injury through suppression of NLRP3 inflammasome-mediated pyroptosis and activation of the Keap1-Nrf2 antioxidant response.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute lung injury (ALI) is a life-threatening respiratory disorder characterized by excessive inflammation and oxidative stress, with no specific pharmacological therapy currently available. Cornuside (CNS), a bioactive iridoid glycoside derived from Methods: Male C57BL/6J mice received intratracheal lipopolysaccharide to induce ALI and intragastric CNS (25 or 50 mg/kg) 1 h before and 3 h after LPS. Lung injury was assessed by survival, wet/dry ratio, bronchoalveolar lavage fluid (BALF) protein, histology, and open-field testing. Oxidative stress was evaluated by MPO, MDA, and GSH-PX assays. Keap1-Nrf2 pathway activation was analyzed by Western blot and immunofluorescence of Keap1, Nrf2, GPX4, and NQO1, including Nrf2 nuclear translocation. Results: CNS significantly improved survival, reduced pulmonary edema, and alleviated lung inflammation and locomotor deficits in LPS-challenged mice. Transcriptomic analysis revealed downregulation of oxidative stress- and inflammation-related pathways. CNS inhibited NLRP3 inflammasome activation, as shown by decreased caspase-1 cleavage, IL-1β release, GSDMD processing, and ASC speck formation Discussion: These findings demonstrate that CNS protects against LPS-induced ALI by concurrently suppressing NLRP3 inflammasome-mediated pyroptosis and enhancing Keap1-Nrf2 antioxidant signaling. This dual mechanism highlights CNS as a promising natural therapeutic candidate for ALI and related oxidative stress-driven lung diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.